PL1636217T3 - 1-Imidazobenzotiazole jako ligandy receptora adenozynowego - Google Patents

1-Imidazobenzotiazole jako ligandy receptora adenozynowego

Info

Publication number
PL1636217T3
PL1636217T3 PL04731369T PL04731369T PL1636217T3 PL 1636217 T3 PL1636217 T3 PL 1636217T3 PL 04731369 T PL04731369 T PL 04731369T PL 04731369 T PL04731369 T PL 04731369T PL 1636217 T3 PL1636217 T3 PL 1636217T3
Authority
PL
Poland
Prior art keywords
sup
benzothiazoles
imidazo
sub
receptor ligands
Prior art date
Application number
PL04731369T
Other languages
English (en)
Inventor
Alexander Flohr
Roland Jakob-Roetne
Roger David Norcross
Claus Riemer
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PL1636217T3 publication Critical patent/PL1636217T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Addiction (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Saccharide Compounds (AREA)
PL04731369T 2003-05-13 2004-05-06 1-Imidazobenzotiazole jako ligandy receptora adenozynowego PL1636217T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP03009842 2003-05-13
EP04731369A EP1636217B1 (en) 2003-05-13 2004-05-06 2-imidazo-benzothiazoles as adenosine receptor ligands
PCT/EP2004/004843 WO2004101558A1 (en) 2003-05-13 2004-05-06 2-imidazo-benzothiazoles as adenosine receptor ligands

Publications (1)

Publication Number Publication Date
PL1636217T3 true PL1636217T3 (pl) 2009-02-27

Family

ID=33395778

Family Applications (1)

Application Number Title Priority Date Filing Date
PL04731369T PL1636217T3 (pl) 2003-05-13 2004-05-06 1-Imidazobenzotiazole jako ligandy receptora adenozynowego

Country Status (15)

Country Link
US (1) US7122545B2 (pl)
EP (1) EP1636217B1 (pl)
JP (1) JP4408291B2 (pl)
KR (1) KR100710453B1 (pl)
CN (1) CN100372844C (pl)
AT (1) ATE407133T1 (pl)
AU (1) AU2004238508B2 (pl)
BR (1) BRPI0410315A (pl)
CA (1) CA2523959A1 (pl)
DE (1) DE602004016328D1 (pl)
ES (1) ES2313001T3 (pl)
MX (1) MXPA05012120A (pl)
PL (1) PL1636217T3 (pl)
RU (1) RU2340612C2 (pl)
WO (1) WO2004101558A1 (pl)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007019417A1 (en) * 2005-08-04 2007-02-15 Sirtris Pharmaceuticals, Inc. Oxazolopyridine derivatives as sirtuin modulators
TW200736252A (en) * 2006-01-27 2007-10-01 Astrazeneca Ab Novel heteroaryl substituted benzothiazoles
TW200813035A (en) 2006-06-19 2008-03-16 Astrazeneca Ab Novel heteroaryl substituted benzoxazoles
TW200901998A (en) 2007-03-06 2009-01-16 Astrazeneca Ab Novel 2-heteroaryl substituted benzothiophenes and benzofuranes
SG10201401169QA (en) * 2009-04-02 2014-05-29 Merck Serono Sa Dihydroorotate dehydrogenase inhibitors
WO2010114971A1 (en) * 2009-04-03 2010-10-07 Sepracor Inc. Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof
US8575336B2 (en) 2011-07-27 2013-11-05 Pfizer Limited Indazoles
WO2016164565A1 (en) * 2015-04-08 2016-10-13 University Of Delaware Trans-cycloheptenes and hetero-trans-cycloheptenes for bioorthogonal coupling
WO2018193090A2 (en) * 2017-04-21 2018-10-25 Amneal Pharmaceuticals Company Gmbh Process for preparation of eliglustat hemitartrate and intermediates thereof
AU2018320673B2 (en) 2017-08-21 2023-03-30 Merck Patent Gmbh Benzimidazole derivatives as adenosine receptor antagonists

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1260444B (it) * 1992-01-24 1996-04-09 Mario Brufani Derivati della 8-(1-amminocicloalchil)1,3-dialchilxantina, procedimenbto di preparazione e loro composizioni farmaceutiche antidepressive, nootropiche e psicostimolanti
US6037473A (en) * 1997-11-13 2000-03-14 Haarmann & Reimer Gmbh Use of substituted benzazoles as UV absorbers, new benzazoles and processes for their preparation
NZ516260A (en) * 1999-07-02 2004-08-27 Eisai Co Ltd Fused imidazole compounds and remedies for diabetes mellitus
KR100571161B1 (ko) * 2000-06-21 2006-04-17 에프. 호프만-라 로슈 아게 벤조티아졸 유도체
MXPA05012369A (es) * 2003-05-21 2006-02-02 Hoffmann La Roche Derivados de benzotiazol y uso de los mismos en el tratamiento de enfermedades relacionadas con el receptor a2a de adenosina.

Also Published As

Publication number Publication date
EP1636217A1 (en) 2006-03-22
JP4408291B2 (ja) 2010-02-03
CN100372844C (zh) 2008-03-05
AU2004238508B2 (en) 2009-11-19
MXPA05012120A (es) 2006-02-08
KR100710453B1 (ko) 2007-04-24
US20040229862A1 (en) 2004-11-18
RU2005138546A (ru) 2006-07-27
AU2004238508A1 (en) 2004-11-25
EP1636217B1 (en) 2008-09-03
WO2004101558A1 (en) 2004-11-25
DE602004016328D1 (de) 2008-10-16
BRPI0410315A (pt) 2006-05-23
KR20060009928A (ko) 2006-02-01
US7122545B2 (en) 2006-10-17
RU2340612C2 (ru) 2008-12-10
ATE407133T1 (de) 2008-09-15
CN1780831A (zh) 2006-05-31
JP2006528215A (ja) 2006-12-14
ES2313001T3 (es) 2009-03-01
CA2523959A1 (en) 2004-11-25

Similar Documents

Publication Publication Date Title
TW200505902A (en) Cannabinoid receptor ligands
NZ541974A (en) Nucleotide phosphoramidates as anticancer agents
MXPA04004674A (es) Ligados de los receptors de los canabinodies.
HK1088845A1 (en) Use of parthenolide derivatives as antileukemic and cytotoxic agents
MX2008000141A (es) Moduladores de lxr basados en imidazol.
WO2004048345A3 (en) 2,5-diketopiperazines for the treatment of obesity
WO2004026248A3 (en) Octahydro-2-h-naphtho[1,2-f] indole-4-carboxamide derivatives as selective glucocorticoid receptor modulators
IL161074A0 (en) Lactam derivatives as antagonists for human 11cby receptors
IL155875A0 (en) Piperazinylpyrazines compounds as antagonists of serotonin 5-ht2 receptor
UA96449C2 (en) Stable laquinimod preparations
MXPA05009367A (es) Antagonistas del receptor opioide.
GEP20115174B (en) Triazolopyrazine derivatives useful as anti-cancer agents
SE0302760D0 (sv) New compounds
EP1861358A4 (en) NOVEL COMPOUNDS, ISOMER THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS VANILLOID RECEPTOR ANAGONIST, AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME
MXPA05013474A (es) Derivados de quinolilamida como antagonistas de ccr-5.
EA200401455A1 (ru) Производные бензоксазина в качестве модуляторов 5-htи их применение
AU2003239389A1 (en) Opioid receptor antagonists
PL1636217T3 (pl) 1-Imidazobenzotiazole jako ligandy receptora adenozynowego
MY138826A (en) 2,7-substituted indoles
HK1077827A1 (en) Diazabicyclononane and-decane derivatives their use as opioid receptor ligands
WO2000073269A3 (en) Nicotine receptor ligands
WO2006029210A3 (en) Acyclic 1,3-diamines and uses therefor
WO2006103544A3 (en) 4-piperazinylthieno [2, 3-d] pyrimidine compounds as platelet aggregation inhibitors
MXPA05005198A (es) Derivados de imidazoquinolina, como ligandos del receptor a3 de adenosina.
MXPA04006113A (es) Derivados de triazoloquinolina utiles como ligandos receptores de adenosina.